Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
RESEARCH TOOLSreports
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -11.64%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights AbCellera's successful transition to a clinical stage biotech with strong liquidity and strategic advancements in key programs and partnerships. However, the company faced challenges with declining revenue and a significant net loss, driven by high R&D expenses and reduced partnership activities.Company Guidance
During the call, AbCellera provided guidance with several key metrics for 2024 and beyond. The company achieved significant milestones, including advancing two programs, ABCL635 and ABCL575, positioned for CTA filings in Q2 2025. They reduced new discovery partnership activities, engaging in two new partnerships and expanding one collaboration, concluding the year with over $800 million in available liquidity. Their transition to a clinical stage biotech is underscored by plans to initiate Phase 1 clinical trials for ABCL635 and ABCL575, nominate additional development candidates, and complete platform investments by mid-2025. Financially, they reported approximately $29 million in revenue, a net loss of $163 million, and ended the year with over $650 million in cash and equivalents. Moving forward, AbCellera is focused on entering the clinic, with priorities including advancing their two lead programs and leveraging their TCE platform for future partnerships.Strong Liquidity Position
AbCellera closed the year with over $800 million in available liquidity, including approximately $650 million in cash and equivalents and roughly $190 million in available committed government funding.
Advancement of Key Programs
The company advanced two programs, ABCL635 and ABCL575, which are positioned for CTA filings in Q2 2025, signaling a successful transition to a clinical stage biotech.
New Headquarters and Manufacturing Facility
Completion of the move into new headquarters and progress towards bringing the clinical manufacturing facility online in 2025.
Strategic Partnership with AbbVie
Entered into a significant partnership with AbbVie based on the TCE platform, highlighting a meaningful collaboration in the TCE space.
---
ABCL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ABCL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $2.92 | $2.58 | -11.64% |
| Nov 04, 2024 | $2.89 | $2.72 | -5.88% |
| Aug 06, 2024 | $2.85 | $2.63 | -7.72% |
| May 07, 2024 | $4.04 | $3.84 | -4.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AbCellera Biologics (ABCL) report earnings?
AbCellera Biologics (ABCL) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is AbCellera Biologics (ABCL) earnings time?
AbCellera Biologics (ABCL) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ABCL EPS forecast?
ABCL EPS forecast for the fiscal quarter 2025 (Q1) is -0.12.
---